Zheng Quan Zhi Xing·2025-07-30 16:13Core Viewpoint - The company intends to use its own funds to pay for part of the investment project and subsequently replace it with raised funds, which is in compliance with regulatory requirements and aims to enhance the efficiency of fund utilization [1][5]. Fundraising Basic Situation - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds, with net fundraising amounting to approximately 253.43 million yuan after deducting related expenses [1][2]. Investment Project Basic Situation - As of June 30, 2025, the total investment for the projects, including the Jiangsu Phase II, Hubei Pharmaceutical Sorting and Processing Center, and Hebei Pharmaceutical Warehouse, amounts to 253.43 million yuan, with 179.74 million yuan allocated from the raised funds [2]. Reasons for Using Own Funds - The company faces challenges in using raised funds directly for certain expenses, such as employee salaries and social insurance, which must be paid through the basic deposit account. Therefore, it plans to use up to 7.05 million yuan of its own funds for these payments and later replace them with raised funds [3][4]. Impact on the Company - The use of self-funds for project payments and subsequent replacement with raised funds is expected to improve fund utilization efficiency and ensure the smooth progress of investment projects without affecting the normal implementation of the projects [4][5]. Review Procedures and Opinions - The company's board and supervisory committee have approved the proposal to use self-funds for the investment project, confirming that this action does not harm the interests of the company or its shareholders and complies with relevant regulations [5].